PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
The conversation discusses the effects of B5 (Pantothenic acid), B7 (Biotin), and B12 on hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses whether finasteride would still be necessary if Verteporfin becomes a successful hair loss treatment. It also explores the sensitivity of transplanted hair to DHT and the potential for off-label use of Verteporfin post hair transplant.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
The user shared their hormone levels over time while using finasteride and dutasteride for hair loss. They experienced a significant drop in DHT levels but continued to lose hair, hoping for better results in the future.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.
Stemoxydine's effects on hair growth are uncertain and not well-studied, with users reporting mixed results and concerns about maintaining gains. Some users combine it with 5AR inhibitors like Dutasteride, but results vary, and conditions like lichen planopilaris complicate treatment.
People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.
A 23-year-old is experiencing hair loss, primarily at the top middle of the head, and is considering finasteride but is hesitant due to potential side effects. Other users share their positive experiences with finasteride, suggesting it is worth trying, while also discussing the importance of researching and monitoring for any side effects.
A user is concerned about low testosterone while using finasteride 0.625mg MWF and considers ashwagandha for stress. Others suggest exercise, magnesium, and not worrying about testosterone levels if no significant side effects are felt.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.
A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.
The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
A 27-year-old man shared his hair regrowth progress after using finasteride for 4 years, recently adding a solution of RU58841 with minoxidil and alfatradiol, tretinoin on temples, and occasional ketoconazole. He is seeking opinions on his treatment approach.
A 30-year-old male has been on finasteride/dutasteride for 3 years, with stable but still receding hairline, and blood tests showing high total testosterone but normal DHT and free testosterone levels. Despite challenges in gaining muscle, he maintains a good physique with a consistent lifting routine and recently improved results with creatine.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
Creatine use is linked to increased hair shedding for some, especially those with DHT sensitivity, but experiences vary. Some users manage hair loss with treatments like finasteride, minoxidil, or dutasteride, while others stop creatine to reduce shedding.
Dutasteride may affect testosterone levels, leading to high ferritin and iron levels, which can cause hair loss. High ferritin might be linked to past heavy drinking or hemochromatosis.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.